Shopping Cart
Remove All
Your shopping cart is currently empty
Zilovertamab vedotin (Synonyms: VLS-101, MK-2140)
Catalog No. T77186 Copy Product Info
🥰Excellent
Zilovertamab vedotin is a novel antibody-drug conjugate (ADC) constructed by conjugating the humanized monoclonal antibody zilovertamab with the anti-microtubule cytotoxic drug monomethyl vedotin. It binds to ROR1 on the surface of tumor cells, promotes rapid internalization and trafficking of the complex to lysosomes, followed by ADC cleavage and release of monomethyl vedotin, thereby inducing tumor cell apoptosis. It can be used in cancer-related research.
Zilovertamab vedotin
Copy Product Info🥰Excellent
Catalog No. T77186
Synonyms VLS-101, MK-2140
Zilovertamab vedotin is a novel antibody-drug conjugate (ADC) constructed by conjugating the humanized monoclonal antibody zilovertamab with the anti-microtubule cytotoxic drug monomethyl vedotin. It binds to ROR1 on the surface of tumor cells, promotes rapid internalization and trafficking of the complex to lysosomes, followed by ADC cleavage and release of monomethyl vedotin, thereby inducing tumor cell apoptosis. It can be used in cancer-related research.
Zilovertamab vedotin
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $758 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $1,990 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Zilovertamab vedotin is a novel antibody-drug conjugate (ADC) constructed by conjugating the humanized monoclonal antibody zilovertamab with the anti-microtubule cytotoxic drug monomethyl vedotin. It binds to ROR1 on the surface of tumor cells, promotes rapid internalization and trafficking of the complex to lysosomes, followed by ADC cleavage and release of monomethyl vedotin, thereby inducing tumor cell apoptosis. It can be used in cancer-related research. |
| In vitro | Zilovertamab vedotin (0–100 μg/mL) induces cytotoxic effects in ROR1+ primary mantle cell lymphoma (MCL) cells in a dose-dependent manner.Following 24-hour treatment, zilovertamab vedotin significantly induces apoptosis and causes cell cycle arrest at the G2/M phase in both the ibrutinib-sensitive cell line (JeKo-1) and the ibrutinib-resistant cell line (JeKo BTK kd2) [1]. |
| In vivo | Zilovertamab vedotin (administered intravenously at 2.5 mg/kg once weekly for 3 consecutive weeks) specifically targets ROR1-expressing patient-derived xenograft (PDX) models that are resistant to both ibrutinib and CAR-T therapy. Studies have confirmed that zilovertamab vedotin effectively inhibits tumor growth in these models [1]. |
| Synonyms | VLS-101, MK-2140 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | MMAE |
| Gene ID | |
| Uniprot ID | |
| Target | ROR1 |
| Molecular Weight | 145.12 kDa |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Zilovertamab vedotin | purchase Zilovertamab vedotin | Zilovertamab vedotin cost | order Zilovertamab vedotin | Zilovertamab vedotin in vivo | Zilovertamab vedotin in vitro | Zilovertamab vedotin molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.